Phase I/III study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer

Annals of Oncology

Volumn 8, Issue 4, 1997, Pages 355-361

  Du Bois, A ^a,f   Luck H J ^b   Bauknecht, T ^c   Mobus V ^d   Bochtler, H ^e   Diergarten, K ^e   Meerpohl, H G ^a  

^a St Vincentius Hospital Karlsruhe   (Germany)

^b LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF ULM   (Germany)

^e BRISTOL MYERS SQUIBB   (United States)

^f Frauenkl St Vincentius K   (Germany)

Author keywords

Carboplatin; Chemotherapy; Neurotoxicity; Ovarian cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG TOLERANCE; FEMALE; HUMAN; INFUSION; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; ADULT; AGED; CARCINOMA; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; FEASIBILITY STUDY; HEMATOLOGIC DISEASE; MIDDLE AGED; OVARY TUMOR; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; FEMALE; HEMATOLOGIC DISEASES; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; TREATMENT OUTCOME;

EID: 0030612632     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008267419453     Document Type: Article

References (21)

1. Omura GA, Brady MF, Homesley HD et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience. J Clin Oncol 1991; 9: 1138-50.
2. Advanced Ovarian Trialists Group. Chemotherapy in advanced ovarian cancer: An overview of randomized clinical trials. BMJ 1991; 303: 884-93.
3. Alberts DS, Green S, Hannigan EV et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer: J Clin Oncol 1992; 10: 706-17.
4. Swenerton K, Jeffrey J, Stuart G et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 1992; 10: 718-26.
5. Mangioni C, Bolis G, Pecorelli S et al. Randomized trial in ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst 1989; 81: 1464-71.
6. Thigpen JT, Blessing JA, Ball H et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum based chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 1994; 12: 1748-53.
7. Trimble EL, Adams JD, Vena D et al. Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute treatment referral center 9103. J Clin Oncol 1993; 11: 2405-10.
8. Kohn EC, Sarosy G, Bicher A et al. Dose-intense Taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994; 86: 18-24.
9. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
10. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-66.
11. Bookmann MA. McGuire III WP, Kilpatrick D et al. Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group. J Clin Oncol 1996; 14: 1895-902.
12. ten Bokkel Huinink WW, Veenhof CHN, Helmerhorst TJM et al. Carboplatin (C) and paclitaxel (P) (TAXOL) in patients with advanced ovarian cancer, a dose-finding study. Proc Am Soc Clin Oncol 1995; 14: 269 (Abstr 746).
13. Siddiqui N, Bailey N, Robson L et al. A phase 1 / pharmacokinetic I study of escalating paclitaxel (P) in combination with carboplatin (C) dosed at a fixed area under the curve (AUC) in epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 1995; 14: 271 (Abstr 752).
14. Bolis G, Scarfone G, Maggi R et al. A dose-finding study with fixed dose of carboplatin and escalating paclitaxel (PTX) in advanced ovarian cancer. Proc Am Soc Clin Oncol 1995; 14: 270 (Abstr 748).
15. Calvert AH, Newell DR, Gumbrell LA. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 17: 1748-56.
16. Jeliffe RW. Creatinine clearance: Bedside estimate. Ann Intern Med 1973; 79: 604 (Letter).
17. Rowinsky EK, Gilbert MR, McGuire WP et al. Sequence of Taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 1991; 9: 1692-703.
18. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
19. Neijt JP. New therapy for ovarian cancer. N Engl J Med 1996; 334: 50-1 (Editorial).
20. NIH Consensus Conference. Ovarian cancer screening treatment, and follow-up. JAMA 1995; 273: 491-7.
21. Rozencweig M, Martin A, Beltangady M. Randomized trials of carboplatin versus cisplatin in advanced ovarian cancer. In Bunn PA, Canetta R, Ozols RF (eds): Carboplatin (JM-8): Current Perspectives and Future Directions. Philadelphia: WB Saunders 1990; 175-86.